Bio-Connect
Aloxistatin [E-64d] [88321-09-9]

Aloxistatin [E-64d] [88321-09-9]

Research Use Only
AG-CR1-3737
AdipoGen Life Sciences
Estimated Purity>98%
Product group Chemicals
Molecular Weight342.4
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Aloxistatin [E-64d] [88321-09-9]
  • Delivery Days Customer
    10
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Non-hazardous
  • Molecular Formula
    C17H30N2O5
  • Molecular Weight
    342.4
  • Scientific Description
    Aloxistatin [E-64d] is a cell permeable irreversible inhibitor of lysosomal and cytosolic cysteine proteases cathepsin B an L, calpain 1/2, papain and has diverse biological activities. It is an ethyl ester form of E-64c that inhibits calpain and the cysteine proteases cathepsins F, K, B, H, and L. Aloxistatin has anticancer properties by inducing cell cycle arret at the G2/M phase in A431 human epidermoid carcinoma cells and as a lysosomal inhibitor in human acute promyelocytic leukemia NB4 cells and Huh-7 cells. It inhibits degradation of autophagic cargo inside autolysosomes. It also shows neuroprotective and anti-malarial properties. Since cysteine protease cathepsin L is required for SARS-CoV-2 viral entry, aloxistatin treatment reduces cellular entry of SARS-CoV-2 pseudovirions and COVID-19. It inhibits severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 surface glycoprotein incorporation into pseudotyped vesicular stomatitis virus (VSV) particles in Vero cells. Is has been applied in vitro in combination with the TMPRSS2 inhibitor camostat mesylate (Prod. No. AG-CR1-3716). - Chemical. CAS: 88321-09-9. Formula: C17H30N2O5. MW: 342.4. Aloxistatin [E-64d] is a cell permeable irreversible inhibitor of lysosomal and cytosolic cysteine proteases cathepsin B an L, calpain 1/2, papain and has diverse biological activities. It is an ethyl ester form of E-64c that inhibits calpain and the cysteine proteases cathepsins F, K, B, H, and L. Aloxistatin has anticancer properties by inducing cell cycle arret at the G2/M phase in A431 human epidermoid carcinoma cells and as a lysosomal inhibitor in human acute promyelocytic leukemia NB4 cells and Huh-7 cells. It inhibits degradation of autophagic cargo inside autolysosomes. It also shows neuroprotective and anti-malarial properties. Since cysteine protease cathepsin L is required for SARS-CoV-2 viral entry, aloxistatin treatment reduces cellular entry of SARS-CoV-2 pseudovirions and COVID-19. It inhibits severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 surface glycoprotein incorporation into pseudotyped vesicular stomatitis virus (VSV) particles in Vero cells. Is has been applied in vitro in combination with the TMPRSS2 inhibitor camostat mesylate (Prod. No. AG-CR1-3716).
  • SMILES
    O=C(OCC)[C@H]1O[C@@H]1C(N[C@H](C(NCCC(C)C)=O)CC(C)C)=O
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200